Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GPR3 | P46089 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoylenurea SCHEMBL29947820 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL30293081 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL530191 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL196018 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL554709 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL29844822 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL6099088 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL4413903 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL3139711 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL6076792 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| WO-2022130352-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021130723-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| EP-3083587-B1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2018-04-04 | — | — | EP | disclosed |
| EP-3083587-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2016-10-26 | — | — | EP | disclosed |
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015107541-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| EP-2864309-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | Cadila Healthcare Limited (IN) | 2015-04-29 | — | — | EP | disclosed |
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | disclosed |
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2014002106-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002105-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | disclosed |
| EP-2658851-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | disclosed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| CN-102596941-A | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LTD | 2012-07-18 | — | — | CN | disclosed |
| WO-2012090220-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | LIPC, HMGCR, PCSK9 | ALDH1A1 1224/4885KDM4E 2751/4885HSD17B10 44/4885 |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | ALDH1A1 1955/4885KDM4E 3462/4885HSD17B10 57/4885 |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | PCSK9, APOB, CPT1A | ALDH1A1 1379/4885KDM4E 3925/4885HSD17B10 69/4885 |
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | OAT, CYP11B2, CYP11B1 | ALDH1A1 1340/4885KDM4E 2149/4885HSD17B10 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.